What is the official website of Revolution Medicines ?

The official website of Revolution Medicines is http://www.revmed.com.

What is Revolution Medicines's cybersecurity risk score?

Revolution Medicines has an AI-generated cybersecurity risk score of 796 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Revolution Medicines experienced?

According to Rankiteo, Revolution Medicines currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Revolution Medicines been affected by any supply chain cyber incidents ?

According to Rankiteo, Revolution Medicines has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Revolution Medicines have SOC 2 Type 1 certification ?

According to Rankiteo, Revolution Medicines is not certified under SOC 2 Type 1.

Does Revolution Medicines have SOC 2 Type 2 certification ?

According to Rankiteo, Revolution Medicines does not hold a SOC 2 Type 2 certification.

Does Revolution Medicines comply with GDPR ?

According to Rankiteo, Revolution Medicines is not listed as GDPR compliant.

Does Revolution Medicines have PCI DSS certification ?

According to Rankiteo, Revolution Medicines does not currently maintain PCI DSS compliance.

Does Revolution Medicines comply with HIPAA ?

According to Rankiteo, Revolution Medicines is not compliant with HIPAA regulations.

Does Revolution Medicines have ISO 27001 certification ?

According to Rankiteo,Revolution Medicines is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Revolution Medicines operate in ?

Revolution Medicines operates primarily in the Biotechnology Research industry.

How many employees does Revolution Medicines have ?

Revolution Medicines employs approximately 574 people worldwide.

Does Revolution Medicines own any subsidiaries ?

Revolution Medicines presently has no subsidiaries across any sectors.

How many LinkedIn followers does Revolution Medicines have ?

Revolution Medicines's official LinkedIn profile has approximately 20,003 followers.

What is the NAICS classification code for Revolution Medicines ?

Revolution Medicines is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does Revolution Medicines have a Crunchbase profile ?

Yes, Revolution Medicines has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/revolution-medicines.

Does Revolution Medicines have a LinkedIn profile ?

Yes, Revolution Medicines maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/revolution-medicines.

How many cybersecurity incidents has Revolution Medicines experienced ?

As of October 8, 2026, Rankiteo reports that Revolution Medicines has not experienced any cybersecurity incidents.

How many peer or competitor companies does Revolution Medicines have ?

Revolution Medicines has an estimated 4,780 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Revolution Medicines

Boost Score +25 with badge (5 left)

796

/1000

Fair

821

/1000

Good

Revolution Medicines Vendor Cyber Rating & Cyber Score

revmed.com

cb in

Add Your Compliance Badge

We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.

Revolution Medicines

Revolution Medicines CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Revolution Medicines Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Revolution Medicines

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Revolution Medicines in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Revolution Medicines in 2026.

Incident Types Revolution Medicines vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Revolution Medicines in 2026.

Incident History - Revolution Medicines (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Revolution Medicines Subsidiaries

Parent Company

Revolution Medicines

Biotechnology Research

Website: http://www.revmed.com

Company Size: 574

No subsidiary data available for this company.

Loading…

Revolution Medicines Similar Companies

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

The National Institutes of Health

cb nih.gov

NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Gilead Sciences

cb gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Loading…

NEWS

Revolution Medicines CyberSecurity News

Global CVEs (Not Company-Specific)

CVE-2026-89322

SUMMARY

Vault and Vault Enterprise did not consistently evaluate ACL policies against the canonical form of resource and policy names. This may allow an authenticated user with delegated permissions to bypass an explicit deny restriction and access a protected resource or assign a denied policy, potentially leading to privilege escalation. This vulnerability (CVE-2026-89322) is fixed in Vault Community Edition 2.1.2, and Vault Enterprise 2.1.2, 1.21.12, 1.20.17, and 1.19.23.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 7.2)

cvss3

Base Score: 7.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.2

REFERENCES

https://discuss.hashicorp.com/t/hcsec-2026-43-vault-inconsistent-acl-policy-evaluation-may-allow-bypass-of-deny-restrictions/77815

CVE-2026-107314

SUMMARY

pgjdbc, the PostgreSQL JDBC Driver, versions 42.7.11 through 42.7.13 enforce no restriction when the requireAuth connection property excludes all six authentication methods the driver knows, for example requireAuth=!password,!md5,!gss,!sspi,!scram-sha-256,!none. The driver then accepts any method the server asks for, including cleartext password authentication. A value without a method in it, such as requireAuth=, (a single comma), is affected the same way. An attacker positioned between the application and its server can ask for cleartext password authentication and receive the database password. A positive list such as requireAuth=scram-sha-256, and a partial exclusion such as requireAuth=!password,!md5, are enforced correctly. The property has no default value, so a deployment that does not set it is not affected. 42.7.14 fixes the problem: such a connection is refused with SQLState 08004, and a value without a method in it is rejected as invalid.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

https://github.com/pgjdbc/pgjdbc/security/advisories/GHSA-rhp9-mr79-r74h

CVE-2026-107285

SUMMARY

The AsyncHttpClient (AHC) library allows Java applications to easily execute HTTP requests and asynchronously process HTTP responses. Prior to 3.0.12 and 2.16.1, a proxied ws request is carried through CONNECT, but NettyRequestFactory.newNettyRequest and requestUri decide whether to attach proxy authentication and an absolute-form target only from whether the URI is secure. Because ws is not marked secure, the tunneled WebSocket upgrade sent to the origin includes the proxy's Proxy-Authorization value. Basic credentials are directly recoverable and Digest responses can be replayed or cracked offline. This issue is fixed in versions 3.0.12 and 2.16.1.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-107284

SUMMARY

The AsyncHttpClient (AHC) library allows Java applications to easily execute HTTP requests and asynchronously process HTTP responses. Prior to 3.0.12 and 2.16.1, WebSocketHandler.upgrade aborts a handshake whose Sec-WebSocket-Accept value is missing or invalid but continues into pipeline installation and onOpen delivery. Frames coalesced with the invalid 101 response can be decoded and delivered from a peer that did not prove the handshake, although the request future fails and the channel closes. This issue is fixed in versions 3.0.12 and 2.16.1.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-107283

SUMMARY

The AsyncHttpClient (AHC) library allows Java applications to easily execute HTTP requests and asynchronously process HTTP responses. Prior to 3.0.12 and 2.16.1, Realm.Builder generates the HTTP Digest client nonce with ThreadLocalRandom rather than a cryptographically secure random source. Digest relies on an unpredictable cnonce to resist chosen-plaintext and credential precomputation attacks, so an observer able to infer generator state can reduce the protection of the authentication exchange. This issue is fixed in versions 3.0.12 and 2.16.1.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Revolution Medicines Vendor Cyber Rating & Cyber Score

Revolution Medicines A.I CyberSecurity Scoring

Revolution Medicines CyberSecurity News & History

Revolution Medicines Company Scoring based on AI Models